| Antibody-drug conjugate, GSK285 in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study |
58 |
| The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion |
57 |
| Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria |
47 |
| Pathogenesis of bone disease in multiple myeloma: from bench to bedside |
41 |
| Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting |
34 |
| Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma |
26 |
| Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts |
25 |
| Myelodysplastic syndromes current treatment algorithm 2018 |
24 |
| Chronic lymphocytic leukemia treatment algorithm 2018 |
20 |
| Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use |
19 |
| Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018 |
18 |
| Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project |
18 |
| Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide |
17 |
| Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome |
17 |
| Current status of autologous stem cell transplantation for multiple myeloma |
16 |
| Essential thrombocythemia treatment algorithm 2018 |
15 |
| Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia? |
15 |
| The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL |
15 |
| Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients |
14 |
| Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies |
14 |
| Polycythemia vera treatment algorithm 2018 |
14 |
| Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells |
13 |
| Disease and outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials |
13 |
| Deciphering the chronology of copy number alterations in Multiple Myeloma |
13 |
| Molecular signatures of multiple myeloma progression through single cell RNA-Seq |
13 |
| Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients |
12 |
| Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia |
12 |
| Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study |
12 |
| Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model |
12 |
| Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma |
12 |
| Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC) |
12 |
| SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia |
11 |
| Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma |
11 |
| Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry |
11 |
| Momelotinib therapy for myelofibrosis: a 7-year follow-up |
10 |
| Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse |
10 |
| GATA2 zinc finger 1 mutations are associated with distinct clinico-biological features and outcomes different from GATA2 zinc finger 2 mutations in adult acute myeloid leukemia |
10 |
| Two types of amyloidosis presenting in a single patient: a case series |
10 |
| A multiple myeloma-specific capture sequencing platform discovers novel translocations and frequent, risk-associated point mutations in IGLL5 |
10 |
| Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group |
10 |
| Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases |
9 |
| Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms |
9 |
| Loss of TNFAIP3 enhances MYD88 L265P(-) driven signaling in non-Hodgkin lymphoma |
9 |
| Deferred autologous stem cell transplantation in systemic AL amyloidosis |
9 |
| Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma |
9 |
| The biological significance of histone modifiers in multiple myeloma: clinical applications |
9 |
| Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma |
9 |
| Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort |
9 |
| Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea |
9 |
| Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma |
9 |
